257 related articles for article (PubMed ID: 30299364)
21. Impact of the duration of antibiotics on clinical events in patients with Pseudomonas aeruginosa ventilator-associated pneumonia: study protocol for a randomized controlled study.
Bouglé A; Foucrier A; Dupont H; Montravers P; Ouattara A; Kalfon P; Squara P; Simon T; Amour J;
Trials; 2017 Jan; 18(1):37. PubMed ID: 28114979
[TBL] [Abstract][Full Text] [Related]
22. Antibiotic-resistant Pseudomonas aeruginosa: focus on care in patients receiving assisted ventilation.
Bassetti M; Villa G; Pecori D
Future Microbiol; 2014; 9(4):465-74. PubMed ID: 24810346
[TBL] [Abstract][Full Text] [Related]
23. Epidemiology and Treatment of Multidrug-Resistant and Extensively Drug-Resistant Pseudomonas aeruginosa Infections.
Horcajada JP; Montero M; Oliver A; Sorlí L; Luque S; Gómez-Zorrilla S; Benito N; Grau S
Clin Microbiol Rev; 2019 Sep; 32(4):. PubMed ID: 31462403
[TBL] [Abstract][Full Text] [Related]
24. Management of multidrug-resistant Pseudomonas aeruginosa in the intensive care unit: state of the art.
Maraolo AE; Cascella M; Corcione S; Cuomo A; Nappa S; Borgia G; De Rosa FG; Gentile I
Expert Rev Anti Infect Ther; 2017 Sep; 15(9):861-871. PubMed ID: 28803496
[TBL] [Abstract][Full Text] [Related]
25. Mechanisms leading to in vivo ceftolozane/tazobactam resistance development during the treatment of infections caused by MDR Pseudomonas aeruginosa.
Fraile-Ribot PA; Cabot G; Mulet X; Periañez L; Martín-Pena ML; Juan C; Pérez JL; Oliver A
J Antimicrob Chemother; 2018 Mar; 73(3):658-663. PubMed ID: 29149337
[TBL] [Abstract][Full Text] [Related]
26. Efficacy of ceftolozane/tazobactam, alone and in combination with colistin, against multidrug-resistant Pseudomonas aeruginosa in an in vitro biofilm pharmacodynamic model.
Gómez-Junyent J; Benavent E; Sierra Y; El Haj C; Soldevila L; Torrejón B; Rigo-Bonnin R; Tubau F; Ariza J; Murillo O
Int J Antimicrob Agents; 2019 May; 53(5):612-619. PubMed ID: 30682497
[TBL] [Abstract][Full Text] [Related]
27. The peculiarities of Pseudomonas aeruginosa resistance to antibiotics and prevalence of serogroups.
Gailiene G; Pavilonis A; Kareiviene V
Medicina (Kaunas); 2007; 43(1):36-42. PubMed ID: 17297282
[TBL] [Abstract][Full Text] [Related]
28. Novel therapies for Pseudomonas aeruginosa pneumonia.
Roux D; Ricard JD
Infect Disord Drug Targets; 2011 Aug; 11(4):389-94. PubMed ID: 21679142
[TBL] [Abstract][Full Text] [Related]
29. Activity of Ceftolozane-Tazobactam against Carbapenem-Resistant, Non-Carbapenemase-Producing Pseudomonas aeruginosa and Associated Resistance Mechanisms.
Wi YM; Greenwood-Quaintance KE; Schuetz AN; Ko KS; Peck KR; Song JH; Patel R
Antimicrob Agents Chemother; 2018 Jan; 62(1):. PubMed ID: 29133568
[TBL] [Abstract][Full Text] [Related]
30. Clinical characteristics and outcomes of Pseudomonas aeruginosa bacteremia in febrile neutropenic children and adolescents with the impact of antibiotic resistance: a retrospective study.
Kim HS; Park BK; Kim SK; Han SB; Lee JW; Lee DG; Chung NG; Cho B; Jeong DC; Kang JH
BMC Infect Dis; 2017 Jul; 17(1):500. PubMed ID: 28716109
[TBL] [Abstract][Full Text] [Related]
31. Ceftolozane and tazobactam for the treatment of hospital acquired pneumonia.
Martin-Loeches I; Bisanti A; Diaz E; Rodriguez A
Expert Rev Anti Infect Ther; 2020 Dec; 18(12):1177-1185. PubMed ID: 32662691
[TBL] [Abstract][Full Text] [Related]
32. Activity of imipenem/relebactam against Pseudomonas aeruginosa with antimicrobial-resistant phenotypes from seven global regions: SMART 2015-2016.
Karlowsky JA; Lob SH; Young K; Motyl MR; Sahm DF
J Glob Antimicrob Resist; 2018 Dec; 15():140-147. PubMed ID: 30071354
[TBL] [Abstract][Full Text] [Related]
33. Evaluation of ceftazidime/avibactam for serious infections due to multidrug-resistant and extensively drug-resistant Pseudomonas aeruginosa.
Rodríguez-Núñez O; Ripa M; Morata L; de la Calle C; Cardozo C; Fehér C; Pellicé M; Valcárcel A; Puerta-Alcalde P; Marco F; García-Vidal C; Del Río A; Soriano A; Martínez-Martínez JA
J Glob Antimicrob Resist; 2018 Dec; 15():136-139. PubMed ID: 30036695
[TBL] [Abstract][Full Text] [Related]
34. Phylogenetic analysis of resistance to ceftazidime/avibactam, ceftolozane/tazobactam and carbapenems in piperacillin/tazobactam-resistant Pseudomonas aeruginosa from cystic fibrosis patients.
Zamudio R; Hijazi K; Joshi C; Aitken E; Oggioni MR; Gould IM
Int J Antimicrob Agents; 2019 Jun; 53(6):774-780. PubMed ID: 30831233
[TBL] [Abstract][Full Text] [Related]
35. Previous ciprofloxacin exposure is associated with resistance to beta-lactam antibiotics in subsequent Pseudomonas aeruginosa bacteremic isolates.
López-Dupla M; Martínez JA; Vidal F; Almela M; Soriano A; Marco F; López J; Olona M; Mensa J
Am J Infect Control; 2009 Nov; 37(9):753-8. PubMed ID: 19487049
[TBL] [Abstract][Full Text] [Related]
36. Verification of Ceftazidime-Avibactam and Ceftolozane-Tazobactam Susceptibility Testing Methods against Carbapenem-Resistant Enterobacteriaceae and Pseudomonas aeruginosa.
Shields RK; Clancy CJ; Pasculle AW; Press EG; Haidar G; Hao B; Chen L; Kreiswirth BN; Nguyen MH
J Clin Microbiol; 2018 Feb; 56(2):. PubMed ID: 29167294
[TBL] [Abstract][Full Text] [Related]
37. Use of Ceftolozane/Tazobactam in the Treatment of Multidrug-resistant Pseudomonas aeruginosa Bloodstream Infection in a Pediatric Leukemia Patient.
Aitken SL; Kontoyiannis DP; DePombo AM; Bhatti MM; Tverdek FP; Gettys SC; Nicolau DP; Nunez CA
Pediatr Infect Dis J; 2016 Sep; 35(9):1040-2. PubMed ID: 27254038
[TBL] [Abstract][Full Text] [Related]
38. Improving the adequacy of empirical beta-lactam therapy for Pseudomonas aeruginosa ventilator-associated pneumonia.
Depuydt P; Blot S; Benoit D; Decruyenaere J
Int J Antimicrob Agents; 2008 May; 31(5):489-90. PubMed ID: 18313271
[No Abstract] [Full Text] [Related]
39. Ceftolozane/tazobactam activity against drug-resistant Enterobacteriaceae and Pseudomonas aeruginosa causing urinary tract and intraabdominal infections in Europe: report from an antimicrobial surveillance programme (2012-15).
Pfaller MA; Bassetti M; Duncan LR; Castanheira M
J Antimicrob Chemother; 2017 May; 72(5):1386-1395. PubMed ID: 28165526
[TBL] [Abstract][Full Text] [Related]
40. Ceftolozane-tazobactam for the treatment of multidrug-resistant
Alessa MA; Almangour TA; Alhossan A; Alkholief MA; Alhokail M; Tabb DE
Am J Health Syst Pharm; 2018 May; 75(9):e184-e188. PubMed ID: 29691260
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
